Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Ashley Ohler

Physician Assistant Slidell, LA Physician Assistant

NPI 1235709510 CMS profile 10521572

1810 Lindberg Dr Ste 2100, Slidell, LA 70458

Open in the dashboard

General payments

$5,768

302 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ashley Ohler of Slidell, LA is reported in the CMS Open Payments database as having received $5,768 across 302 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $213 12
2024 General $1,537 96
2023 General $1,335 74
2022 General $1,569 86
2021 General $1,113 34

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ashley Ohler
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Ashley Ohler were reported at $213. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Ashley Ohler Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $1,113 $132 $37–$438 $132
2022 $1,569 $155 $48–$522 $149
2023 $1,335 $167 $52–$557 $160
2024 $1,537 $178 $55–$600 $164
2025 $213 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Novartis Pharmaceuticals Corporation $1,034 65 payments
  2. Pfizer Inc. $517 33 payments
  3. Impulse Dynamics (USA) Inc. $476 3 payments
  4. Merck Sharp & Dohme Corporation $419 25 payments
  5. Amgen Inc. $378 30 payments
  6. Janssen Pharmaceuticals, Inc $374 25 payments
  7. AstraZeneca Pharmaceuticals LP $357 14 payments
  8. Boehringer Ingelheim Pharmaceuticals, Inc. $252 15 payments
  9. Actelion Pharmaceuticals US, Inc. $228 9 payments
  10. Esperion Therapeutics, Inc. $190 12 payments
  11. Other $1,542 71 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $5,468 301 payments
  2. Consulting Fee $300 1 payment
Products named General payments · program years 2021–2025
  1. VERQUVO $573 34 payments
  2. ELIQUIS $517 33 payments
  3. LEQVIO Cardiology/Vascular Diseases $509 43 payments
  4. Optimizer Smart System $476 3 payments
  5. XARELTO $374 25 payments
  6. Repatha $362 29 payments
  7. FARXIGA $333 13 payments
  8. LEQVIO Cardiovascular $279 7 payments
  9. PAXLOVID $255 17 payments
  10. JARDIANCE $199 12 payments
  11. Other $2,702 138 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

302 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record